FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (w…
The FDA has granted Priority Review to Johnson & Johnson's supplemental Biologics License Application for IMAAVY (nipocalimab-aahu) as a potential treatment for warm autoimmune hemolytic anemia. The decision is based on results from the Phase 2/3 ENERGY study, which showed IMAAVY achieved a durable hemoglobin response and improved fatigue compared to placebo.
The U.S. Food and Drug Administration (FDA) has granted Priority Review to Johnson & Johnson's supplemental Biologics License Application (sBLA) for IMAAVY (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA). IMAAVY is designed to target the underlying cause of wAIHA by reducing circulating immunoglobulin G autoantibodies. The FDA's decision is supported by results from the pivotal Phase 2/3 ENERGY study, which showed that more patients treated with IMAAVY achieved a durable hemoglobin response compared with placebo. The study also showed improvements in fatigue, a critical outcome for people living with wAIHA. Warm autoimmune hemolytic anemia is a rare, life-threatening condition where autoantibodies destroy red blood cells, resulting in anemia. IMAAVY is not currently approved by the U.S. FDA for the treatment of wAIHA.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.